<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03053141</url>
  </required_header>
  <id_info>
    <org_study_id>91087667</org_study_id>
    <nct_id>NCT03053141</nct_id>
  </id_info>
  <brief_title>RHythmia mAPping and Signal acquisitiOn for Data analYsis (RHAPSODY)</brief_title>
  <acronym>RHAPSODY</acronym>
  <official_title>RHythmia mAPping and Signal acquisitiOn for Data analYsis (RHAPSODY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the RHAPSODY study is to evaluate the performance of new software features&#xD;
      in subjects undergoing standard of care catheter-based endocardial mapping for atrial or&#xD;
      ventricular tachyarrhythmias using a commercial Rhythmia Mapping System. Results from this&#xD;
      study will be used to guide development and refinement of new software features that may be&#xD;
      implemented in future commercial software releases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Rhythmia Mapping System is designed for electroanatomical mapping in catheter ablation&#xD;
      procedures by optimizing the need for speed and accuracy. The system is able to&#xD;
      simultaneously acquire data from multiple electrodes. In addition, based on user-defined&#xD;
      criteria, the system is able to efficiently acquire data over multiple cardiac beats. When&#xD;
      used in conjunction with the Rhythmia Mapping Catheter, the system is able to acquire up to&#xD;
      hundreds of points per minute leading to fast and detailed map creation.&#xD;
&#xD;
      Since its market release, physicians and users have gained experience with the Boston&#xD;
      Scientific Rhythmia Mapping System in the human clinical setting. Improvements to the first&#xD;
      generation system are in development and include new and improved software features and&#xD;
      mapping algorithms to enhance the clinical operation. These new and improved software&#xD;
      features and algorithms require leveraging clinical use data as part of the development and&#xD;
      iteration process.&#xD;
&#xD;
      This study will evaluate the performance of potential next-generation software features in a&#xD;
      low-risk clinical environment by streaming raw signals from a commercial Rhythmia Workstation&#xD;
      during standard of care cardiac mapping and ablation treatments for tachyarrhythmias,&#xD;
      specifically atrial fibrillation, atrial tachycardias, and ventricular tachycardia. The data&#xD;
      will be evaluated on a parallel investigational Rhythmia Workstation using prototype software&#xD;
      features. These next-generation software features and algorithms will not be available to the&#xD;
      physician during the case and will therefore have no diagnostic or therapeutic impact on the&#xD;
      clinical case.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Physician Feedback on Software Performance</measure>
    <time_frame>1 day- Procedure</time_frame>
    <description>Physician Feedback on Software Performance</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cardiac Arrythmias</condition>
  <arm_group>
    <arm_group_label>All Subjects</arm_group_label>
    <description>All subjects are included in this cohort and are treated with the Rhythmia Mapping System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rhythmia Mapping System</intervention_name>
    <description>The Rhythmia Mapping System is a 3D electro-anatomical mapping system.</description>
    <arm_group_label>All Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for standard of care catheter-based endocardial mapping for atrial or&#xD;
        ventricular tachyarrhythmias using a commercial Rhythmia Mapping System.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 or above, or above legal age and willing and capable of giving informed consent&#xD;
             specific to national law&#xD;
&#xD;
          2. Scheduled for standard of care catheter-based endocardial mapping for atrial or&#xD;
             ventricular tachyarrhythmias using a commercial Rhythmia Mapping System.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prothrombotic or bleeding tendency due to coagulopathy or blood dyscrasia&#xD;
&#xD;
          2. Inability to tolerate heparin therapy (e.g. heparin induced thrombocytopenia, allergy,&#xD;
             etc.)&#xD;
&#xD;
          3. Prosthetic or stenotic valves in the chamber where the intended mapping will occur, or&#xD;
             in the path of the catheter access route&#xD;
&#xD;
          4. Active systemic infection or sepsis&#xD;
&#xD;
          5. Hemodynamic instability or shock at baseline precluding ablation in the assessment of&#xD;
             the investigator.&#xD;
&#xD;
          6. Presence of intracardiac thrombus, tumor, or other abnormality which precludes&#xD;
             catheter introduction&#xD;
&#xD;
          7. Women who are pregnant or lactating&#xD;
&#xD;
          8. Cardiac surgery within the past 90 days&#xD;
&#xD;
          9. Acute myocardial infarction within 3 months&#xD;
&#xD;
         10. Stable/unstable angina or ongoing myocardial ischemia&#xD;
&#xD;
         11. Subjects with an active heart failure decompensation&#xD;
&#xD;
         12. Long QT Syndrome, Brugada Syndrome, or Torsade de Pointes&#xD;
&#xD;
         13. Congenital heart disease with or without corrective surgery that would complicate a&#xD;
             mapping procedure&#xD;
&#xD;
         14. Subjects having untreatable allergy to contrast media&#xD;
&#xD;
         15. Vascular pathology or tortuosity precluding standard vascular access techniques&#xD;
&#xD;
         16. Subjects who are currently enrolled in another investigational study or registry that&#xD;
             would directly interfere with the current study, except when the patient is&#xD;
             participating in a mandatory governmental registry, or a purely observational registry&#xD;
             with no associated treatments. Each instance should be brought to the attention of the&#xD;
             sponsor to determine eligibility.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas H McElderry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rami Guirguis</last_name>
    <email>rami.guirguis@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarfaraz Taher</last_name>
    <email>Sarfaraz.Taher@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>St. Lukes Idaho Cardiology Associates</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon LaMott</last_name>
      <phone>208-388-7216</phone>
      <email>lamotts@slhs.org</email>
    </contact>
    <investigator>
      <last_name>Marcos Daccarett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catholic Medical Center</name>
      <address>
        <city>Manchester</city>
        <state>New Hampshire</state>
        <zip>03102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Moritz</last_name>
      <phone>603-665-2444</phone>
      <email>lori.moritz@cmc-nh.org</email>
    </contact>
    <investigator>
      <last_name>Jamie Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450-2736</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Centro San Raffaele</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Princesse Grace</name>
      <address>
        <city>Monaco</city>
        <zip>98000</zip>
        <country>Monaco</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Rijo</last_name>
      <phone>37797988445</phone>
      <email>nicolas.rijo@chpg.mc</email>
    </contact>
    <investigator>
      <last_name>Decebal-Gabriel Latcu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Monaco</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>February 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2017</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

